pegfilgrastim

merger virtual handshake

Pharma

Coherus sells Neulasta biosimilar to Intas for up to $558M

Coherus has scored up to $558 million for the last biosimilar in its portfolio, freeing up the company to go all.in on Loqtorzi.

Fraiser Kansteiner Dec 3, 2024 4:16pm

FDA Building 2

FDA reprimands Amgen for 'misleading’ Neulasta banner ad

Jul 15, 2021 10:20am